Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03771105 · ClinicalTrials.gov registry record · Early Phase 1

The Impact of Phosphate Metabolism on Healthy Aging

A Early Phase 1 study, sponsored by Yale University.

Recruiting
Registry status
Early Phase 1
Development phase
30
Enrollment target

NCT03771105 is a Early Phase 1 study that is actively recruiting participants, run by Yale University. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03771105, a Early Phase 1 study, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Early Phase 1
Development phase
30 participants
Enrollment target

Study Summary

Determine the association between duration and dose of chronic conventional therapy with Pi and renal (nephrocalcinosis/nephrolithiasis), vascular (endothelial function), and cardiovascular function (echo- cardiography) in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) and patients with X-linked hypophosphatemia (XLH).

Interventions

  • DRUG phosphate

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2019-01-01
Est. Completion 2028-04
Phase Early Phase 1

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT03771105

The ClinicalTrials.gov registry entry for NCT03771105 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which phosphate is the first listed.

NCT03771105 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03771105 about?

NCT03771105 is a clinical study titled "The Impact of Phosphate Metabolism on Healthy Aging". Determine the association between duration and dose of chronic conventional therapy with Pi and renal (nephrocalcinosis/nephrolithiasis), vascular (endothelial function), and cardiovascular function (echo- cardiography) in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) ...

What is the current status of trial NCT03771105?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2019-01-01. Estimated completion is 2028-04.

What interventions are being tested in trial NCT03771105?

The interventions under investigation include: phosphate (DRUG).

Who is sponsoring clinical trial NCT03771105?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.